Status In progress
Process TAG

Provisional Schedule

Expected publication 02 December 2020

Timeline

Key events during the development of the guidance:

Date Update
29 March 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late January 2020 when we will write to you about how you can get involved.
22 March 2019 Proposed, As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late January 2020 when we will write to you about how you can get involved.
22 March 2019 In progress, As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during late January 2020 when we will write to you about how you can get involved.
17 October 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance